Eisai’s affiliates in China are wholly-owned by Eisai Co., Ltd. (Eisai), a Japanese multinational pharmaceutical company with strong R&D capabilities, as global headquarter in Tokyo and headquarter of China in Shanghai.
Eisai has grown smoothly since entering the Chinese market in the early 1990s and the total …
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that presentations on a series of abstracts highlighting updates on its oncology products and pipeline will be given at the European Society for Medical Oncology (ESMO) Virtual Congress 2021, from September 16 to 21, 2021, including its in-house discovered lenvatinib mesylate (product name: LENVIMA®, an orally available multi-kinase inhibitor, “lenvatinib”) and eribulin mesylate (product name: HALAVEN®, a halichondrin class microtubule dynamics inhibitor, “eribulin”).
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has received the Award for Excellence in Corporate Communications at the 37th annual Corporate Communications Awards, hosted by the Japan Institute for Social and Economic Affairs (Tokyo, Chairman: Masakazu Tokura), an affiliate of the Japanese Business Federation (Tokyo).
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that the company will conduct a total of 11 presentations, including the latest data of the investigational anti-amyloid beta (Aβ) protofibril antibody lecanemab (development code: BAN2401) for which the U.S. Food and Drug Administration has granted Breakthrough Therapy designation, at the Alzheimer’s Association International Conference (AAIC) to be held in Denver, Colorado and virtually from July 26 to 30, 2021.
CAMBRIDGE, Mass. and TOKYO, JULY 8,2021(GLOBE NEWSWIRE) – Biogen (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced the U.S. Food and Drug Administration (FDA) has approved an updated label for ADUHELM™ (aducanumab-avwa) injection 100 mg/mL solution.
Shanghai Tenry Pharmaceutical Company Limited (hereinafter referred to as "Shanghai Tenry") and Eisai China Inc. signed a marketing service agreement. Shanghai Tengry is responsible for the market promotion of Glufast® (Mitiglinide Calcium Tablets), a diabetes treatment drug, in China, and the two parties will work hand in hand to serve the vast population of diabetic patients in China.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
Essential Website Cookies
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
Other external services
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds: